Skip to Content
Laurent Levy PhD
Chief Executive Officer

Laurent Levy is the co-founder of Nanobiotix and has served as Chief Executive Officer since March 2003. He was first appointed as Chairman of the Executive Board on May 27, 2004. Laurent has extensive experience in sciences and techniques related to nanotechnologies. His research at the frontier of biotechnology and nanotechnologies has resulted in the development of several concrete applications including Nanobiotix lead product candidate NBTXR3, which could expand therapeutic options and improve outcomes for patients with cancer.

Laurent's mission goes beyond simply curing major diseases like cancer. He and his team are on a mission to unlock humanity's limitless potential or, as they call it, to "Expand Life". From exploring the use of nanotechnology to increase processing power and reshape the brain, to resolving the issues of rapid therapeutic clearance to revolutionize the paradigm of how intravenously administered treatments are designed and delivered--and much more. Mr. Levy's true goal is to help inspire humanity to push beyond boundaries and discover a better way of life. Defeating cancer with the team at Nanobiotix and NBTXR3 is the first step, but only one of many on a bold journey.

From 2000 to 2003, prior to the founding of Nanobiotix, Laurent served as consultant for Altran Technologies and worked in the development of the application of nanotechnologies with companies such as Sanofi S.A., Guerbet S.A., and Rhodia S.A., as well as for early-stage biotechnology companies. He has served as President of the Supervisory Board of Valbiotis S.A. (Euronext Paris: ALVAL) since March 2017, was Vice Chairman of the Executive Board of the European Technology Platform on Nanomedicine (ETPN) from December 2012 to June 2019 and as a founding member of the Nanomedicine Translation Advisory Board (a division of ETPN) from June 2014 to June 2019.

Laurent has authored more than 35 international scientific publications and communications, has applied for and secured several patents, and regularly speaks on the topic of using nanoparticles to fight cancer and other diseases. He holds a Doctorate in Physical Chemistry, specializing in nanomaterials, from the Pierre and Marie Curie University (Université Paris VI Pierre et Marie Curie; UPVI-ESPCI) in Paris and from the CEA (Commissariat à l’Énergie Atomique et aux Énergies Alternatives), and a DEA (advanced studies and diplomas) in Physics of Condensed Matter from the UPVI-ESPCI. Laurent completed his studies with a post-doctoral fellowship at the Institute for Lasers, Photonics and Biophotonics at the State University of New York at Buffalo (SUNY Buffalo). Nanobiotix was created as a spinoff based on the findings from his post-doctoral thesis.

Photo of Laurent Levy, PhD Chief Executive Officer
Bart Van Rhijn
Chief Financial Officer
Mr. Van Rhijn brings extensive experience in consultancy, technology, and life sciences industries and joins Nanobiotix after nearly 3 years as chief financial officer at Servier Pharmaceuticals, LLC (Servier US). Prior to Servier US, he held leadership roles in prominent organizations in Europe and North America, including PricewaterhouseCoopers, Philips and Galderma in Head of Tax, Senior Director of Mergers and Acquisitions, and Head of Finance positions. Mr. Van Rhijn’s track record reflects a relentless commitment to streamlining business operations, driving growth, and unlocking value. His varied experiences include the successful reorganization of a healthcare technology-enabled services business, coordination of strategic financing transactions, and the efficient scaling of commercial businesses. Mr. Van Rhijn has a strong commitment to organizational health and empowers his teams to embrace innovation, challenge the status quo, and drive optimal results while putting patients and customers first.

Mr. Van Rhijn received master’s degrees in Civil Law and Tax Law at Leiden University, The Netherlands, obtained his MBA with honors from Babson’s Olin School of Management, and his Certified Management Accountant (CMA) certification from the Institute of Management Accounts. In addition, Mr. Van Rhijn serves on the Advisory Board of a Boston-based healthcare start-up and is a venture partner at an emerging technology fund.
Bart Van Rhijn, Chief Financial Officer
Anne-Juliette Hermant
Chief People Officer

Anne-Juliette Hermant brings over 14 years in talent management and development acquired in different entities at AXA. She worked at AXA Partners for 3 years as Global Head of Talent, Development, Culture and Corporate Responsibility. Before AXA Partners, Anne-Juliette served as Chief Learning Officer of the AXA Group and was the Founder and Head of the AXA Research Fund, a €100 million fund created by the AXA Group to support frontier science in all fields related to an understanding of the risks faced by human society.

Anne-Juliette was born in Strasbourg, France and grew up between the French Caribbean islands of Guyane, Martinique and Guadeloupe. She relocated to Paris to pursue her studies and has remained in the city throughout her career.

Anne-Juliette studied French literature at the Ecole Normale Supérieure and Politics at Sciences Po Paris.

Photo of Anne-Juliette Hermant, Chief People Officer